Kawoya Kijjali Joseph

Dr. Kawoya Kijjali Joseph


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
Maiya Grace Block NgaybeMaiya Grace Block Ngaybe
Maiya Grace Block Ngaybe
RMRichard Muhumuza
Richard Muhumuza
MAMélanie Antunes
Mélanie Antunes
EMEzra Musingye
Ezra Musingye
Kawoya Kijjali JosephKawoya Kijjali Joseph
Kawoya Kijjali Joseph
Purnima MadhivananPurnima Madhivanan
Purnima Madhivanan
Background: Human immunodeficiency virus (HIV) affects more than 39 million people worldwide, with Uganda ranked 10th among countries with the highest number of cases. As new preventative HIV injectables emerge, it is vital to think about how best to tailor strategies to promote these injectable drugs, like PrEP and vaccines, when available, to the different populations most in need. Discrete choice experiments (DCEs) are economics-derived methods used to determine factors that influence engagement in a certain behavior. Objective: This study used a DCE to determine the preferences for a preventative HIV injectable drugs/vaccines among people at risk of HIV acquisition in urban and peri-urban areas of Uganda. Methods: In June 2024, we implemented a cross-sectional DCE survey in three urban sites in Uganda in English and Luganda. The survey collected information on demographics, HIV risk, vaccine confidence and responses to the 13 injection product choice tasks presented to determine preferences. We used community-based, respondent-driven sampling methods to recruit participants from three key populations: (1) female sex workers; (2) people who identify as lesbian, gay, bisexual or transgender; and (3) young women (18–24 years). We collected the data on tablets using the Sawtooth Lighthouse Studio software (v. 19.15.6), taking into consideration privacy and confidentiality, given the sensitivity of the information and recent governmental policies in Uganda. Data were analyzed using a split-sample mixed logit regression analysis. The study was approved by local ethical regulatory bodies. Results: From the total of 406 participants screened for this study, 376 participants met the eligibility criteria and were included in the final analysis (85 young women, 159 female sex workers, and 132 who identified as lesbian, gay, bisexual or transgender). The average age was 23.7 (SD: 5.7). The majority of participants had received some secondary school or vocational school (202, 53.7%) The attributes that explained the preferences were primarily severe compared to mild side effects (β: −0.69, 95% CI: −0.78, −0.60), a 30% increase in vaccine/drug effectiveness (β: 0.39, 95% CI: 0.34, 0.44), and a 50,000 UGX (or USD ~13.64) increase in cost (β: −0.22, 95% CI: −0.27, −0.17). There were no significant differences between the preferences for different injectable types. The sensitivity analyses suggested potential differences in preferences by the amount of help participants received from research assistants when completing the survey, although not by income level. Conclusions: Side effects had the greatest impact on participants’ preferences for injectable HIV prevention methods, followed closely by effectiveness and cost. It is therefore essential to develop affordable or free prevention options with minimal side effects. Policymakers should focus on reducing the financial barriers to access and emphasize transparent communication about the effectiveness and safety of these injectables in health promotion campaigns to maximize adoption and improve public health outcomes.

16 December 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
Maiya Grace Block NgaybeMaiya Grace Block Ngaybe
Maiya Grace Block Ngaybe
Kawoya Kijjali JosephKawoya Kijjali Joseph
Kawoya Kijjali Joseph
WHWadana Hamzazai
Wadana Hamzazai
CDCarly Jo Deal
Carly Jo Deal
SMStephen Mugamba
Stephen Mugamba
Purnima MadhivananPurnima Madhivanan
Purnima Madhivanan
Background/Objectives: Long-acting injectable pre-exposure prophylaxis (PrEP) has recently been approved for use, and dissemination, but has yet to be released in Uganda. To ensure uptake of this injectable option, and others like a future HIV vaccine, it is important to understand the preferences of the populations at the highest risk who will benefit the most. We present data on product preferences for HIV prevention practices and injectable HIV prevention among populations most at risk for HIV with a focus on injectable options such as long-acting PrEP or a future HIV Vaccine for primary prevention of HIV. Methods: In March 2024, we conducted 20 semi-structured key informant interviews in English and Luganda among 10 experts in the field of HIV prevention, and 10 peer leaders of key or priority populations in Uganda. Participants were purposively selected to represent various groups, genders, occupations and locations to get diverse perspectives. Both groups of participants were asked similar questions, with experts focusing on their experience with key populations. Debriefs were held after each interview to monitor emerging themes and assess data saturation. Data were analyzed using a thematic analysis guided by Lancaster’s consumer theory. Results: The most common prevention practices mentioned by participants were condoms and PrEP. Participants mentioned barriers to prevention practices including duration, accessibility issues such as transportation, location issues and stigma. The most important characteristics for participants when considering the uptake of a new injectable prevention product included efficacy, cost and side effects. Experts tended to have higher minimal acceptable efficacy percentages. Participants who were peer leaders recognized that some had a fear of needles, though they also expressed motivation to receive injections due to the perception that they may work better than other modes of administration. Conclusions: According to experts and peer leader participants in this study, key populations in Uganda prefer high efficacy, lower side effects and confidentiality in their services. Participants emphasized the need for comprehensive and accessible information about specific HIV prevention methods to improve the uptake of these products. Tailored messaging and choice can accommodate the heterogeneity of preferences to best ensure HIV prevention in Uganda.